Hu et al., 2018 - Google Patents
A quantitative chemotherapy genetic interaction map reveals factors associated with PARP inhibitor resistanceHu et al., 2018
View HTML- Document ID
- 7084408209534326950
- Author
- Hu H
- Zhao X
- Kaushik S
- Robillard L
- Barthelet A
- Lin K
- Shah K
- Simmons A
- Raponi M
- Harding T
- Bandyopadhyay S
- Publication year
- Publication venue
- Cell reports
External Links
Snippet
Chemotherapy is used to treat most cancer patients, yet our understanding of factors that dictate response and resistance to such drugs remains limited. We report the generation of a quantitative chemical-genetic interaction map in human mammary epithelial cells charting …
- 230000003993 interaction 0 title abstract description 94
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hu et al. | A quantitative chemotherapy genetic interaction map reveals factors associated with PARP inhibitor resistance | |
Peng et al. | Genome-wide transcriptome profiling of homologous recombination DNA repair | |
Srivas et al. | A network of conserved synthetic lethal interactions for exploration of precision cancer therapy | |
Matulonis et al. | Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials | |
Camidge et al. | Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed | |
Yoon et al. | KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach | |
Takahashi et al. | Replication stress defines distinct molecular subtypes across cancers | |
Yang et al. | A c-Myc-regulated stem cell-like signature in high-risk neuroblastoma: A systematic discovery (Target neuroblastoma ESC-like signature) | |
Guerrero Llobet et al. | An mRNA expression-based signature for oncogene-induced replication-stress | |
Lokeshwar et al. | Molecular oncology of bladder cancer from inception to modern perspective | |
Han et al. | Genetic interaction-based biomarkers identification for drug resistance and sensitivity in cancer cells | |
Papalouka et al. | DNA damage response mechanisms in head and neck cancer: significant implications for therapy and survival | |
Gu et al. | A landscape of synthetic viable interactions in cancer | |
Sun et al. | Cell cycle arrest is an important mechanism of action of compound Kushen injection in the prevention of colorectal cancer | |
Ryan et al. | Complex synthetic lethality in cancer | |
Yu et al. | A meta‐analysis: micro RNA s’ prognostic function in patients with nonsmall cell lung cancer | |
Qin et al. | Biomarkers for predicting abiraterone treatment outcome and selecting alternative therapies in castration‐resistant prostate cancer | |
Li et al. | Comprehensive analysis reveals USP45 as a novel putative oncogene in pan-cancer | |
Chan et al. | Clinical implications of systemic and local immune responses in human angiosarcoma | |
Kang et al. | Aberrant transcript usage is associated with homologous recombination deficiency and predicts therapeutic response | |
Aprile et al. | Targeting metabolism by B-raf inhibitors and diclofenac restrains the viability of BRAF-mutated thyroid carcinomas with Hif-1α-mediated glycolytic phenotype | |
Orme et al. | Co-occurring BRCA2/SPOP mutations predict exceptional poly (ADP-ribose) polymerase inhibitor sensitivity in metastatic castration-resistant prostate cancer | |
Joy et al. | AKT pathway genes define 5 prognostic subgroups in glioblastoma | |
Shan et al. | A novel epithelial‐mesenchymal transition molecular signature predicts the oncological outcomes in colorectal cancer | |
Belcastro et al. | Systematic verification of upstream regulators of a computable cellular proliferation network model on non-diseased lung cells using a dedicated dataset |